Highline Wealth Partners’s iShares Biotechnology ETF IBB Stock Holding History

Highline Wealth Partners’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$39K	Hold	205	–	–	0.01%	271
2026 Q1	$34.6K	Sell	205 -25	-11%	-$4.28K	0.01%	215
2025 Q4	$38.8K	Hold	230	–	–	0.01%	156
2025 Q3	$33.2K	Hold	230	–	–	0.01%	192
2025 Q2	$29.1K	Buy	230 +25	+12%	+$3.07K	0.01%	175
2025 Q1	$26.2K	Hold	205	–	–	0.01%	175
2024 Q4	$27.1K	Hold	205	–	–	0.01%	161
2024 Q3	$29.8K	Sell	205 -106	-34%	-$15.3K	0.01%	156
2024 Q2	$42.7K	Buy	311 +162	+109%	+$21.6K	0.02%	133
2024 Q1	$20.5K	Buy	+149	New	+$20.3K	0.01%	172

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Highline Wealth Partners's IBB Position: Q2 2026 in Review

Highline Wealth Partners held its iShares Biotechnology ETF (IBB) position steady in Q2 2026 at 205 shares worth $39K. The position accounts for 0.01% of the portfolio, ranked #271.

Highline Wealth Partners first reported a position in IBB in Q1 2024 and has held it in 10 quarters since. The position peaked at $42.7K in Q2 2024. 956 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

Highline Wealth Partners held 205 shares of iShares Biotechnology ETF worth $39K as of Q2 2026.
Highline Wealth Partners left its iShares Biotechnology ETF share count unchanged in Q2 2026.
iShares Biotechnology ETF made up 0.01% of Highline Wealth Partners's portfolio in Q2 2026, its #271 holding.
Highline Wealth Partners first reported a position in iShares Biotechnology ETF in Q1 2024 and has held it in 10 quarters since.
Highline Wealth Partners's iShares Biotechnology ETF position peaked at $42.7K in Q2 2024.
956 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Highline Wealth Partners's 13F filing for Q2 2026, filed 15 Jul 2026.